AUTHOR INDEX

Andrews P. 129
Armstrong, D. A. J. 1

Bonner, D. P. 321
Buchwald, H. 93

Cayen, M. N. 157
Chiba, P. 111
Cline, M. J. 69
Cory, J. G. 111

Diana, G. D. 287

Elford, H. L. 239

Fitch, L. 93
Fujii, A. M. 221

Goldfarb, M. P. 205

Kim, D. H. 49
Kornalík, F. 353

Lione, A. 255

McKinlay, M. A. 287

Otto, M. J. 287

Pestka, S. 299

Rowland, M. 49

Swabb, E. A. 321
Sykes, R. B. 321

Tarnowski, S. J. 299

Van Arman, C. G. 1
van't Riet, B. 239
Varco, R. L. 93
Vatner, S. F. 221

Whitfield, J. F. 407

Youdale, T. 407

SUBJECT INDEX

Acetaminophen structure 36
Acetanilide structure 36
Acifran 182
Acipimox 179, 180
Allometry 62–66
Aluminium
  absorption 257, 258
  anaemias 267
  analysis in samples 255–57
  antacids 271–73
  aspirins 273, 274
  chelation 271
  excretion 260, 261
  intoxication
    diagnosis 269, 270
    treatment 270, 271
  medications 274, 275
  mineral metabolism 266, 267
  osteodystrophy 265, 266
  parathyroid gland 267, 268
  parenteral 258
  plasma binding 258, 259
  reference materials 257
  renal function 268
  sucral fate 274
  toxicology 255–77
  vaccines 275, 276
Ancrod 363–65
  experimental uses 389, 390
Anion exchange resins, drug interactions 184, 185
Antibiotics, β-lactam 321–47 *see also* individual antibiotic groups
  development 323
  limitations 346
  structures of natural 322
Antihyperlipidaemic agents *see also* individual drugs
  anion-exchange resins 186–86
  half-lives 185
  interactions between 187, 188
  liver effects 188–91
  pharmacokinetics 157–91
Antimalarials
  structure 14
  synthetic 19
Antipyretics 1–39
  ancient 20, 21
  assay methods 4–10
  cat 9
  drug comparisons 6
  drug families 10–39 *see also* individual drugs
  guinea-pig 10
  man 4–6
  mode of action 1, 2
  monkey 9, 10
  mouse 9
  rabbit 8, 9
  rat 6–8
Antipyrene, volume of distribution 63
Anti-schistosomal activity 129–51
AraC in combination chemotherapy 121, 122
Arildone structure 290
Aroylarylalkanoic acids structures 31
Arylalkanoic acids 29, 30
N-Arylanthranilic acids 29
Aryloxyarylalkanoic acids 30, 31
Aspirin, U.S. deaths 24
Atherosclerosis
  partial ileal bypass 93–103
  surgical intervention 93–108
Autonomic control, myocardial contractility 221–35
Aztreonam pharmacokinetics–342

Batroxobin 365, 366
  experimental uses 389, 390
B cell malignancies
  c-*abl* in leukaemia 208, 209
  c-*myc* expression 205–8
  translocation breakpoints 206
Bezafibrate 176, 177
Blood coagulation
  physiology 353–61
  plasmatic system 357
  scheme 358
  and snake venom enzymes 361–97
Botrocetin, platelet effects 381

Cancer, non-viral oncogenes 205–15
Carbapenem
  microbiology 334–38
  pharmacology 337, 338
  structures 335
Ceftazidime, serum pharmacokinetics 331
Cephalosporins 328–31
  microbiology 328–30
  pharmacology 320, 321
  structure and development 329
Cephalosporins 331–34
  microbiology 331–33
  pharmacology 333, 334
  structural development 332
Chinchophen 22
Chinoin-123 180
Chloroquine structure 20
Ciprofibrate 178, 179
Clofibrate 158–70
  absorption 159
  analysis 158
  biotransformation 166–68
  blood levels 159–61
  congeners 176–9
  distribution 165, 166
  drug interactions 164, 165
  drug metabolism 170
  kidney disease 168–70
  liver disease 168–70
  protein binding 162–64
  salts and prodrugs 161, 162
Clofibric acid 161
Clotting factors 356

Combination chemotherapy
  nucleoside diphosphate reductase inhibition 249
  ribonucleotide reductase target 111–14
Convulxin, platelet effects 378, 379
Crotalase 366, 367
Cytosine arabinoside, combination chemotherapy 120–24

Dantrolene sodium structure 29
Deoxyadenine, nucleoside diphosphate reductase 117–19
4′-6′-Dichloroflavan structure 295
γ-Dichroine 20–22
Diketone moiety, antiviral activity 287, 288
Distribution, physiologic modelling 51–54

Ecarin
  experimental uses 390–92
  prothrombin assay 392
Elimination, physiologic monitoring 54–59
Enolic acids, structures of antipyretics 27, 28
Epinephrine and myocardial contractility 227–29
Exercise and myocardial contractility 224–26

Febrifugine 20, 21
Fenofibrate 177, 178
  biotransformation 177
Fever and prostaglandins 2
Fibrinogen
  lysis by plasmin 361
  structure 360
Fibrogenases 370–72
  properties 370, 371
  snake venom 371
Fluoropyrimidines in combination chemotherapy 120–23
FX, snake venom effects 376–78

Gemfibrozil 179
Gene insertion techniques 70
  chromosome 71–74
  microinjection 80, 81
Genes, c-*ras* transforming 211–14
Gene therapy 69–88
  human disease 84–88
Gene transfer
  cell proliferation 69
  expression 73, 74
  principles 69, 70
  regulation 73, 74
  retroviral vectors 74–80
  techniques 71–73
Genetic transformation, haematopoietic cells 81–84

Haematopoietic cells
  genetic transformation 81–84
  retroviral vectors 83, 84
  transfection 82, 83
Haemorrhage
  heart epinephrine 230
  and myocardial contractility 226
Hepatic clearance modelling 56–58
High performance chromatography, protein purification 300–302

Hydroxybenzohydroxamic acids and compounds
  antineoplastic effects 248–51
  antitumour actions 240–43
  combination chemotherapy 249–51
  DNA pool sizes 247, 248
  dopa-like 245, 246
  iron complexes 244
  mechanism of action 243–45
  mushroom cytobiotic factors 246, 247
  nucleoside diphosphate reductase inhibition 239–52
  structural features 240–43
  synergism in leukaemia 250, 251
Hyperlipidaemias
  lipid ratios 106, 107
  POSCH trial 105–107
  surgical control 104–107
    changes 105, 106
  treatment 107

Imipenem pharmacokinetics 337
Immunoaffinity chromatography 309–12
  automated 311, 312
  features 312, 313
  large scale 310, 311
Indanecarboxylic acids 31
Indoleacetic acids 32
Indomethacin structure 32
Inhibitors
  DNA polymerase 119, 120
  dihydroxypeptidase 336
  β-lactamase 343–45
  nucleoside diphosphate reductase 114–19, 239–52
  picornavirus uncoating 287–96
Interferon purification 299–316
  animal 316
  human fibroblast 313–15
  human leucocyte 299–307
    amino acid sequences 306, 307
    carbohydrate 307
    HPLC 300–303
    multiple species 305
  immune, IFN-γ 315
  recombinant human leucocyte 307–13
    immunoaffinity chromatography 309–12
    immunosorbent 308
    scheme 307
  specific activities 304

β-Lactamase inhibition 343–45
  microbiology 343–45
  pharmacology 345
  structures 344
Leukaemia, c-*abl* expression 208, 209
Liver, antihyperlipidaemic effects 188–91

Malaria 12–14
  drug resistance 15
  pyrogenic blood 13
  red cell lysis 16
α-Melanocyte-stimulating hormone (α-MSH), antipyretic 38, 39
Methotrexate
  dose–body weight 65
  half-life and body weight 64
Mifobate 182

Modelling *see also* physiologic
  physiologically based perfusion 59
  recirculation 61
Monobactams
  microbiology 338–41
  pharmacology 341–3
  structures of natural 340, 341
Muscle wasting 3
Myeloma, c-*mos* activation 210, 211
Myocardial contractility 221–35
  arterial baroreflex 222, 223
  catecholamines 227–29
  chemoreflex 223, 224
  denervation 233–35
  exercise 224–26
  haemorrhage 226
  parasympathetic control 222
  receptor blockades and drugs 234
  sympathetic control 221, 222
  sympathetic–parasympathetic interaction 229–33

Neomycin and antihyperlipidaemic agents 186
Nicotinic acid 170–76
  analogues 179–81
  analysis and absorption 171
  biotransformation 175, 176
  blood levels 171–74
  distribution 174
  drugs liberating 173
Norepinephrine
  arterial pressure 231
  autonomic blockade on heart 232
  and myocardial contractility 228
Nucleoside diphosphate reductase
  DNA polymerase 112, 113
  inhibitors 114–16, 239–52
    combination 116–19
  properties 114
  reaction catalysed 112
  reduction 111–24

Oncogenes
  c-*onc* amplification 209, 210
  non-viral cancer role 205–15
Oxacephems 331–34
  microbiology 331–33
  pharmacology 333, 334
  structural development 332
Oxazolopyridines, structures of antipyretics 35, 36

Pamaquine structure 19
Partial ileal bypass 93–108
  angina changes 101
  animal experiments 93–95
  arteriography 101–103
  complications 97
  effect on cholesterol 94, 99
  hyperlipidaemia 104
  lipid changes 98
  lipid metabolism 99, 100
  postoperative observations 100, 101
  side effects 97, 98
  technique 95, 96
Penicillins
  microbiology 324–26
  pharmacology 326, 327
  structural development 325
Phenacetin structure 36

Phospholipase A_2
  anticoagulant 384, 385
  platelet effects 381–84
Physiologic modelling
  distribution 51–54
  elimination 54–59
    hepatic 56–58
    renal 58, 59
  integrated 59–61
  pharmacokinetic 49–66
    examples 60
  scheme 50
  tissue events 50–59
Picornavirus uncoating inhibitors 287–96
  carbon bridge 289
  diketone moiety 287, 288
  in vitro 291, 292
  in vivo 292, 293
  mode of action 293
  structures 289–91
Piperacillin pharmacokinetics 327
Platelet activation
  scheme 355
  snake venom effects 378–84
Polycycloaromatic alkanoic acids structures 33, 34
Praziquantel 129–51
  assay methods 130
  carbohydrate metabolism 144
  cestode effects 146
  conformation 129
  efficacy 134
  enzyme effects 145
  fate of parasite 148–51
  mammalian effects 147
  mechanism of action 136–48
  metabolic scheme 132
  muscular contraction 137, 138
  oral and serum levels 132
  pharmacokinetics 130–36
  primary effects 139–43
  Schistosoma infection 134
  secondary effects 143–48
  tegument effects 138, 139
  trematode effects 146
  uptake and calcium 135
Primaquine 20
Probucol 181, 182
  structure 181
Prostaglandin, antiinflammatory drugs 37
Protein, *ras* comparison 212
Prothrombin
  ecarin activation 374
  snake venom action 372–76
  structure 359
Pyridinol carbamate 180, 181

Quinghaosin structure 23
Quinine
  antipyretic 10–23
  malaria effects 17
  structures 11
Quinidine structure 11
Quinolines
  antipyretic 10–23
  ring 17–23
  substituted, properties 18

Renal clearance, physiologic modelling 58, 59
Reptilase-R, diagnostic uses 388, 389

Retroviral vectors 74
  design 78–80
  genes inserted 78
  genome 75, 76
  model 77
  production 76, 77
Ribonucleotide reductase
  calf thymus 409
  E. coli and mammalian 407–18
    comparison criteria 409
  M1 component 412, 413
  rat liver cell 411
  structure 408
  synthesis burst 415
  synthesis, M1 and M2 414–16
Russel's viper venom, diagnostic uses 386–88

Salicylates *see also* aspirin
  antipyretics 23–27
  structures 25–27
Schistosomes
  drug uptake 136
  praziquantel effects 138–48
β-Sitosterol 186
Snake venom enzymes *see also* individual compounds
  anticoagulant action 384–86, 393
  blood coagulation 361–97
  clinical uses 392–97
  defibrinating effects 393–95
  diagnostic uses 386–92
  fibrinogen 363–72
  fibrinogenases 370–72
  FX effects 376–78
  platelet effects 378–84
  procoagulant hemostasis 395–97
  prothrombin action 372–76
  species producing 364
  thrombic proteases 364–69
Species scaling 62–66
Sphaeroplast fusion 72
Steroids, antipyretic 37, 38

Tetrahydroquinolines structure 18, 19
Thalassemia
  bone marrow transfection 85
  gene therapy 85
  HSV tk sequence 86, 87
Thrombic proteases 364–69
  properties 368, 369
Thrombocytin, platelet effects 380, 381
Tolbutamide, extraction ratio 55
Transfection 71, 72
Translocation, c-*myc* 207, 208

WIN 51711, mechanism of action 293, 294